Treatment of Graves?? Disease
نویسندگان
چکیده
منابع مشابه
Prognostic Factors in the Relapse of Graves’ Disease Following Treatment with Antithy-roid Drugs
Background: Patients with Graves’ disease exhibit a considerable rate of relapse after treatment with antithyroid drugs and require ablative therapy. Objective: The purpose of this study was to evaluate variables which can be used as prognostic factors in predicting the outcome of Graves’ disease after treatment with antithyroid drugs. Methods: Age, sex, duration of antithyroid drug therapy, pr...
متن کاملRetrospective study of clinical course and treatment response in Graves’ disease [Persian]
In this report, the clinical course and treatment response of 210 patients with Grawes’ disease referred to the research institute for nuclear medicine were studied. The disease was more common in 3rd and 4th decades and more frequent in women (F/M=4). Treatment response with antithyroid drugs was about 50%, whereas 80% of the patients treated by I-131 showed positive response. There was ...
متن کامل[Practical diagnosis and treatment of Graves' disease].
1.診断 (1)Basedow 病を疑う Basedow 病診断の第 1 歩はもちろん疑うことであ る.疑うきっかけは,体重減少,疲れやすい,動悸, 手指振戦,微熱,頻脈,低コレステロール血症など何 らかの代謝亢進を思わせる症状である.眼球突出は特 徴的な症状であるが,眼症状が軽いケースに気づくに はかなり経験が必要である.びまん性甲状腺腫もわか りにくいケースも多い. (2)診断のための検査 1)TSH と甲状腺ホルモン:甲状腺機能亢進症(甲状 腺中毒症)の診断は血液検査だけでよい.スクリーニ ングとして測定するのは TSH と遊離 T4 の 2 つでよ い.この 2 つが正常であれば甲状腺疾患は現在の症状 には関係していないと言い切れる.甲状腺疾患による 甲状腺機能亢進症であれば TSH は 0.01 μU ml 以下 に抑制され,遊離 T4 が上昇している.遊離 T4 が上昇 ...
متن کاملTreatment of Graves’ Disease During Pregnancy
Graves’ disease is an autoimmune syndrome where thyroid stimulating antibodies bind to and activate the thyrotropin receptor on thyroid cells resulting in hyperthyroidism (Weetman, 2000; Jonklaas, 2011). Specifically, the production of thyroid-stimulating immunoglobulin (TSI) and thyroid-stimulating hormone-binding inhibitory immunoglobulin (TBII) act on the thyroid stimulating hormone receptor...
متن کاملGraves' disease development during sizofiran treatment.
It has been reported that various types of immunoactivators can induce Graves' disease. We describe here a case of Graves' disease during treatment with sizofiran, an immunoactivator. A 42-year-old woman who had previously been in an euthyroid state with Hashimoto's thyroiditis, experienced thyrotoxicosis during continuous administration of sizofiran as immunotherapy for endometrial carcinoma. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Nervous and Mental Disease
سال: 1903
ISSN: 0022-3018
DOI: 10.1097/00005053-190303000-00012